Santaris Pharma to Begin Phase II Development of miRNA-Targeting HCV Drug
September 23, 2010
Santaris Pharma to Begin Phase II Development of miRNA-Targeting HCV Drug
While the company remains optimistic about the drug's potential, questions remain as to whether Santaris has the intellectual property necessary to bring it to market.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 5, 2012 / Gene Silencing News - Santaris Nears End of Phase II Trial of miRNA HCV Rx, Seeks Partnership Since GSK Opted Out
September 15, 2011 / Gene Silencing News - EPO to Hear Mirrx Request for Resumption of Patent Proceedings Covering miRNA Rx Technology
January 20, 2011 / Gene Silencing News - Santaris Sues Mirrx Founder Over Blockmir Technology
May 6, 2010 / Gene Silencing News - Santaris Plans Phase II Trial of miRNA-Targeting HCV Drug
April 29, 2010 / Gene Silencing News